US · Healthcare · Biotechnology
EPS came in at -0.11 against a street estimate of -0.46 — a beat of 76.1%.
Analysts rate AnaptysBio Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $87.25.
| Fund | Stake |
|---|---|
| EcoR1 Capital, LLC | 26.36% |
| BlackRock Inc | 6.17% |
| TANG CAPITAL MANAGEMENT LLC | 4.45% |
| State Street Corp | 4.30% |
| Morgan Stanley - Brokerage Accounts | 3.32% |
| Vanguard Capital Management, LLC | 3.03% |
| Affinity Asset Advisors, LLC | 2.76% |
| Sanofi | 2.75% |
| Document | Date |
|---|---|
| Current report · Q1 FY2027 ANAPTYSBIO, INC. – 8-K FILING SUMMARY HEADLINE NUMBERS • Report Date: September 21, 2026 • Reporting Period: Three months and transitional fiscal ye | 2026-09-21 |
| Shareholder vote results · Q1 FY2027 ANAPTYSBIO, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held August 11, 2026 • Company trades on Nasdaq under ticker symbol ANA | 2026-08-11 |
| Reg FD disclosure · Q1 FY2027 ANAPTYSBIO, INC. – 8-K SUMMARY HEADLINE NUMBERS • No financial data provided in this filing BUSINESS & SEGMENT HIGHLIGHTS • Company is a Delaware- | 2026-07-30 |
| Proxy statement · Q4 FY2026 ANAPTYSBIO, INC. – PROXY STATEMENT SUMMARY HEADLINE NUMBERS • Record date: June 22, 2026 • Outstanding shares entitled to vote: 29,608,481 common sh | 2026-06-29 |
| Material agreement · Q4 FY2026 ANAPTYSBIO, INC. - 8-K SUMMARY (June 15, 2026) BUSINESS & SEGMENT HIGHLIGHTS • AnaptysBio entered into a Sublease Agreement on June 15, 2026, to sub | 2026-06-22 |
| Reg FD disclosure · Q2 2026 ANAPTYSBIO, INC. - 8-K SUMMARY HEADLINE NUMBERS • No financial metrics, revenue figures, or numerical results disclosed in this filing • Document da | 2026-05-29 |
| Quarterly report · Q3 FY2026 ANAPTYSBIO, INC. - 10-Q SUMMARY Q1 2026 (Period Ended March 31, 2026) --- HEADLINE NUMBERS • Cash and cash equivalents: $248.5 million (March 31, 2 | 2026-05-12 |
| Annual report FY2025 ANAPTYSBIO, INC. — 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: AnaptysBio, Inc. (Nasdaq: ANAB), clinical-stage biotech focused on | 2026-03-03 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Split | 15 : 10 effective Apr 20, 2026 | 2026-04-20 |
| Announcement | Date |
|---|---|
| Q2 2026 results, FDA approvals expected, litigation judgment anticipated AnaptysBio announced strong financial results driven by robust growth in Jemperli, its lead oncology drug. Key highlights: Jemperli generated $644 million in global sales for the first six m | 2026-09-21 |
| Board authorizes $100 million stock repurchase plan AnaptysBio announced three significant corporate actions on March 27, 2026. First, the company is proceeding with a spin-off of First Tracks Biotherapeutics into a separate public company. S | 2026-03-27 |
| Spin-off of biopharma operations into separate public company announced AnaptysBio announced plans to separate its business into two public companies by Q2 2026 (possibly late April). The company will split into: (1) AnaptysBio (renamed royalty management compan | 2026-03-03 |
| Board authorizes $100 million stock repurchase plan amendment AnaptysBio announced on November 21, 2025 that its Board of Directors authorized an amendment to expand its stock repurchase program. The company is adding $100 million in repurchase authori | 2025-11-21 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for AnaptysBio Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.